Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice

A. Dabrowska; Adam Giermasz; J. Golab; M. Jakóbisiak

Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice

A. Dabrowska, Adam Giermasz, J. Golab, M. Jakóbisiak

Research output: Contribution to journal › Article › peer-review

Abstract

Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.

Original language	English (US)
Pages (from-to)	358-361
Number of pages	4
Journal	Neoplasma
Volume	48
Issue number	5
State	Published - 2001
Externally published	Yes

Keywords

Interferon alpha
Interleukin 12
Melanoma
Mice

ASJC Scopus subject areas

Cancer Research

Fingerprint Dive into the research topics of 'Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice'. Together they form a unique fingerprint.

Cite this

@article{638d4e6b232a470ab7d406f67b07c431,

title = "Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice",

abstract = "Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.",

keywords = "Interferon alpha, Interleukin 12, Melanoma, Mice",

author = "A. Dabrowska and Adam Giermasz and J. Golab and M. Jak{\'o}bisiak",

year = "2001",

language = "English (US)",

volume = "48",

pages = "358--361",

journal = "Neoplasma",

issn = "0028-2685",

publisher = "Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences",

number = "5",

}

TY - JOUR

T1 - Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice

AU - Dabrowska, A.

AU - Giermasz, Adam

AU - Golab, J.

AU - Jakóbisiak, M.

PY - 2001

Y1 - 2001

N2 - Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.

AB - Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.

KW - Interferon alpha

KW - Interleukin 12

KW - Melanoma

KW - Mice

UR - http://www.scopus.com/inward/record.url?scp=0035209760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035209760&partnerID=8YFLogxK

M3 - Article

C2 - 11845979

AN - SCOPUS:0035209760

VL - 48

SP - 358

EP - 361

JO - Neoplasma

JF - Neoplasma

SN - 0028-2685

IS - 5

ER -